Lasa Supergenerics Ltd (LASA) — shareholding pattern, promoter holding, financials and share price
About Lasa Supergenerics Ltd (LASA)
Lasa Supergenerics Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as LASA and on the BSE under scrip code 540702. Its ISIN is INE670X01014.
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. [1]
Lasa Supergenerics Limited is engaged in manufacturing, trading, and producing chemicals, pharmaceuticals, and veterinary APIs, with comprehensive capabilities in research, production, and marketing.
The company specializes in catalyst chemistry and is among India's largest producers of anthelmintic and veterinary API products, with significant production capacity at its facilities in Maharashtra.
Listed peers in Pharmaceuticals: Sandu Pharmaceuticals Ltd, Roopa Industries Ltd, JFL Life Sciences Ltd, Parmax Pharma Ltd, Medi Caps Ltd.
Valuation & Returns
10 Jul 2026At ₹7.5 a share on 10 Jul 2026, Lasa Supergenerics Ltd (LASA) was valued at a price-to-book of 0.45x on a book value of ₹16.71 per share as of Mar 2025. Solomo computes return on equity of -40.71% and return on capital employed of -39.86% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 0.45x
- EPS (TTM)
- ₹-6.8
- Book value / share
- ₹16.71
- ROE
- -40.71%
- ROCE
- -39.86%
- ROA
- -33.57%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- -112.17%
- 52-week range
- ₹7.21 – ₹7.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Lasa Supergenerics Ltd (LASA) reported revenue of ₹25 crore, net profit of ₹-34 crore and earnings per share of ₹-6.8. That compares with revenue of ₹142 crore and net profit of ₹-15 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹-0.13 crore and net profit ₹-4.16 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 137 | 130 | 104 | 142 | 25 |
| Net profit (₹ cr) | -5 | -39 | -22 | -15 | -34 |
| EPS (₹) | -1.31 | -7.71 | -4.34 | -2.95 | -6.8 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -3.16% | 1.28% | 36.52% |
| Profit growth | - | - | 32.08% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 53.65% of Lasa Supergenerics Ltd (LASA) (unchanged from the previous quarter). Promoters have pledged 20.7% of their holding. Market capitalisation was ₹38 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.
Largest disclosed public shareholders in Mar 2026: HUF 2.34%, MAHENDRA GIRDHARILAL WADHWANI 1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 53.65% | 20.7% | - | - | 46.35% |
| Dec 2025 | 53.65% | 20.7% | - | - | 46.35% |
| Sep 2025 | 53.65% | 20.7% | - | - | 46.35% |
| Jun 2025 | 53.65% | 20.7% | 0.47% | - | 46.35% |
| Mar 2025 | 53.65% | 20.7% | - | - | 46.35% |
| Dec 2024 | 53.65% | 20.7% | - | - | 46.35% |
| Sep 2024 | 53.65% | 20.7% | 0.01% | - | 46.35% |
| Jun 2024 | 53.65% | 20.7% | - | - | 46.35% |